MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- , the leading pioneer in clinical trial technology, today released a comprehensive research report titled . The report, based on a survey of clinical trial professionals specializing in endocrinology research, emphasizes the critical role of user-centric eCOA (electronic clinical outcome assessment) technologies in addressing the unique challenges faced by the industry.
The answers to several survey questions highlight the importance of patient-centricity in endocrinology clinical trials: "At YPrime, we understand that every therapeutic area has its own unique challenges and requirements," said Mike Hughes, Chief Product Officer at YPrime. "By closely collaborating with patients, site staff, and sponsors, we develop eCOA solutions tailored to the specific needs of endocrinology trials. Our user-centric approach ensures that our technologies are not only cutting-edge but also intuitive and easy to use, ultimately leading to better patient engagement, higher data quality, and faster study timelines.
" The report also highlights the growing adoption of connected devices in endocrinology clinical trials, with 44% of respondents already leveraging these technologies, primarily for at-home patient monitoring – and another 46% considering adoption. In related news, the launch of its groundbreaking glucometer functionality, which integrates seamlessly with its eCOA platform. Developed in close collaboration with patients living with di.
